Clinical trials: Endometrial Neoplasms
Endometrial Cancer, Obesity
Adipocytokines in Endometrial Cancer
The number of women diagnosed with uterine cancer continues to rise each year. Since the early 1990s, there has been almost 55% rise in the United Kingdom (UK). 34% of endometrial cancer can be attributed to obesity.
- Trial name
- NCT04697264
- Testing
- Blood and tissue sample collection from patients
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- University of Surrey
Endometrial Cancer
Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer
The goal of this study is to (i) improve detection of sentinel nodes and (ii) reduce additional surgical dissection that is needed in case a sentinel lymph node cannot be detected.
- Trial name
- NCT04511026
- Testing
- Lymphoseek, Single Photon Emission Computed Tomography (SPECT), Indocyanine Green (ICG)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University
Endometrial Cancer
Evaluation of Outcomes in Women Undergoing Multimodality Treatment for Advanced Stage Endometrial Carcinoma
Patients with FIGO stage III endometrial carcinoma often require multimodality adjuvant therapy to improve survival and recurrence rates; however, the optimal adjuvant therapy sequence is yet to be established.
- Trial name
- NCT04743999
- Testing
- Quality of life questionnaire
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Henry Ford Health System
Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma
Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Stage IV Endometrial Carcinoma
- Trial name
- NCT00095979
- Testing
- ixabepilone
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Endometrial Cancer
BKM120 as Second-line Therapy for Advanced Endometrial Cancer
This is a prospective multi-center, open-label, single arm, Phase II study to investigate the safety and efficacy of BKM120 in patients with advanced endometrial carcinoma whose disease progressed on or after a first-line…
- Trial name
- NCT01289041
- Testing
- BKM120
- Where
- 42 sites in United States, Australia and 11 more
- Volunteers
- 70 people
- Sponsor
- Novartis Pharmaceuticals
Endometrial Cancer
Hysteroscopic Lymphatic Mapping for Endometrial Cancer
The goal of this clinical research study is to learn if a procedure called intraoperative (during surgery) lymphatic mapping can be used to find the sentinel lymph node in patients with endometrial cancer.
- Trial name
- NCT00671606
- Testing
- Intraoperative Lymphatic Mapping
- Where
- 2 sites in United States
- Volunteers
- 5 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Solid Tumor
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
The purpose of this study will be to evaluate the safety, tolerability, and pharmacological activity of pemigatinib in subjects with advanced malignancies.
- Conditions
- Lung Cancer, Solid Tumor, Gastric Cancer, Urothelial Cancer
- Trial name
- NCT02393248
- Testing
- Pemigatinib, Gemcitabine, Pembrolizumab
- Where
- 20 sites in United States, Denmark
- Volunteers
- 201 people
- Sponsor
- Incyte Corporation
Endometrial Neoplasms
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed…
- Trial name
- DUO-E (NCT04269200)
- Testing
- olaparib, durvalumab, Carboplatin
- Where
- 201 sites in United States, Australia and 20 more
- Volunteers
- 805 people
- Sponsor
- AstraZeneca
Triple Negative Breast Cancer, Endometrial Cancer
A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors
This is an open-label, multi-center, non-randomized, Phase 1b/2 study to assess the safety and efficacy of fruquintinib in combination with tislelizumab in patients with locally advanced or metastatic solid tumors.
- Conditions
- Triple Negative Breast Cancer, Endometrial Cancer, Solid Tumor, Unspecified, Adult, Colorectal Cancer
- Trial name
- NCT04577963
- Testing
- Fruquintinib, Tislelizumab
- Where
- 16 sites in United States
- Volunteers
- 52 people
- Sponsor
- Hutchmed
Uterine Cervical Cancer, Endometrial Cancer
Clinical Trial of PM00104 (Zalypsis®) in Patients With Advanced and/or Metastatic Endometrial or Cervical Cancer Previously Treated With One Line of Systemic Chemotherapy
This study is a phase II clinical and pharmacokinetic trial of PM00104 (Zalypsis®) in patients with advanced and/or metastatic endometrial or cervical cancer previously treated with one line of systemic chemotherapy to evaluate…
- Trial name
- NCT00900562
- Testing
- Zalypsis ( PM00104)
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- PharmaMar
Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
This phase I trial studies the side effects and best dose of raptor/rictor-mammalian target of rapamycin (mTOR) (TORC1/2) inhibitor MLN0128 when given in combination with bevacizumab in treating patients with glioblastoma, a type…
- Conditions
- Adult Glioblastoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma
- Trial name
- NCT02142803
- Testing
- Bevacizumab, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Ovarian Cancer
FPA150 in Patients With Advanced Solid Tumors
This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
- Trial name
- FPA150-001 (NCT03514121)
- Testing
- FPA150, Pembrolizumab
- Where
- 18 sites in United States, South Korea
- Volunteers
- 95 people
- Sponsor
- Five Prime Therapeutics, Inc.
Ovary Cancer, Cervix Cancer
Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.
The purpose of the trial is to evaluate efficacy and safety of continued treatment with tisotumab vedotin.
- Conditions
- Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer
- Trial name
- NCT03245736
- Testing
- Tisotumab Vedotin
- Where
- 4 sites in United States, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Seagen Inc.
Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast or uterine cancer.
- Conditions
- Breast Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Uterine Corpus Cancer
- Trial name
- NCT02874430
- Testing
- Metformin Hydrochloride, Doxycycline
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Complex Atypical Hyperplasia, Endometrial Cancer
Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients
Purpose: This is an open label, single-arm, single-center study of the addition of metformin to standard levonorgestrel-releasing intrauterine device (LR-IUD) treatment of 30 evaluable non-surgical patients with either complex…
- Trial name
- NCT02035787
- Testing
- Metformin
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Endometrial Cancer, Uterine Carcinosarcoma
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
To demonstrate the efficacy and safety of the combination of rucaparib, bevacizumab and atezolizumab in recurrent, progressive endometrial carcinoma.
- Trial name
- EndoBARR (NCT03694262)
- Testing
- Rucaparib, Bevacizumab, Atezolizumab
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Medical College of Wisconsin
Atypical Endometrial Hyperplasia, Endometrial Carcinoma
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
This phase II trial studies how well megestrol acetate with or without pterostilbene works in treating patients with endometrial cancer undergoing hysterectomy.
- Trial name
- NCT03671811
- Testing
- Megestrol Acetate, Pterostilbene
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- City of Hope Medical Center
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma
Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
This randomized surgical window trial evaluates the effect of adding entinostat to medroxyprogesterone acetate before surgery works on progesterone receptors on endometrioid endometrial tumors.
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
- Trial name
- NCT03018249
- Testing
- Entinostat, Hysterectomy, Laboratory Biomarker Analysis
- Where
- 234 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Adrenocortical Adenoma, Endometrial Stromal Sarcomas
Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492
To provide medical follow-up to patients exposed to BGG492 for more than 28 days in study CBGG492A2207 (NCT 01147003) and/or CBGG492A2212 (NCT 01338805).
- Trial name
- NCT02150213
- Testing
- MRI, CT or ultrasound was permitted if MRI was contraindicated, Dexamethasone Supression Test, Sonogram
- Where
- 20 sites in United States, Germany and 4 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Endometrial Cancer
Doxorubicin Hydrochloride Liposome and Carboplatin in Treating Patients With Recurrent, Stage III, or Stage IV Primary Endometrial Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00470067
- Testing
- carboplatin, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Roswell Park Cancer Institute